 Legacy studies employing a single treatment course of two infusions seven days apart demonstrated greatest benefit in three early studies Data support further investigation of novel genetically modified cell therapy in Crohns disease FLORHAM PARK, N.J., Jan. 06, 2023 GLOBE NEWSWIRE Celularity Inc. Nasdaq: CELU Celularity, a biotechnology company developing placental-derived allogeneic cell and biomaterial therapies, ... The post Celularitys Placental-Derived Allogeneic Cell Therapy Pro... 